BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:35Pharma readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies 35Pharma's drugs run\, from Clini
 calTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07143448-234@assetmemo.bio
DTSTAMP:20261121T004537Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:HS235: Phase 1/2 readout est. (NCT07143448)
DESCRIPTION:HS235\, phase 1/2\, Pulmonary Arterial Hypertension.\nStudy: A 
 Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in A
 dults\nEstimated primary completion: March 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/hs235#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07143448
URL:https://assetmemo.bio/drug/hs235#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07123779-234@assetmemo.bio
DTSTAMP:20261121T004537Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:HS235: Phase 1/2 readout est. (NCT07123779)
DESCRIPTION:HS235\, phase 1/2\, Heart Failure.\nStudy: HS235 Study in Overw
 eight and Obese Participants With Combined Pre and Post-Capillary Pulmonar
 y Hypertension Due to Heart Failure With Preserved Ejection Fraction\nEsti
 mated primary completion: January 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/hs235#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07123779
URL:https://assetmemo.bio/drug/hs235#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
